Countdown to Partnering - John Carroll, Editor of Fierce Biotech

John Carroll, editor of Fierce Biotech, shares what he won't miss at the 2011 BIO International Convention.

TOP TEN 'CAN'T MISS' BREAKOUT SESSIONS

201 - FDA – TOWNHALL (Achieving Regulatory Approval and Compliance)  [2]
Wednesday
2:00 pm - 3:30 pm

• Outline key FDA organizational and policy initiatives.
• Present FDA's views on critical topics such as FDAAA/PDUFA V, drug safety, transparency, and Critical Path regulatory science programs.
• Stimulate interactive discussion with respect to the initiatives and issues presented.

97 - Personalized Oncology: The Emergence of Personalized Medicine Strategies in Oncology Clinical Development and Deal Making (Diagnostics & Personalized Medicine) [3]
Tuesday
2:00 pm - 3:30 pm

• Understand scientific and market trends toward personalized medicine in oncology.
• Understand technology challenges of translating biomarkers into clinical use.
• Understand regulatory challenges of translating biomarkers into clinical use and into the marketplace.

261 - Addressing the Major Medical Challenges of Today with Personalized Medicine: Cancer, Diabetes and Brain Injury (Diagnostics and Personalized Medicine)  [4]
Tuesday 
10:00 am - 11:30 am

• Review the latest achievements in developing targeted anti-cancer vaccines. Learn the potential new approaches to diabetes diagnosis and treatment based on understanding of the genetic causes of the disease.
• Learn how the development of biomarkers for TBI can impact diagnosis, management and treatment of brain injured patients.

199 - Starting Up Biotechs in the New Normal World (Finance) [5]
Wednesday
10:00 am – 11:30 am

• Provide CEO and VC views on how biotech venture fundraising has changed between early 2008 and 2011.
• Review non-VC funding options for start-up biotechs.
• Provide an interactive forum for entrepreneurs to ask questions.

196 - Wait, Our Model Isn't Dead! We Just Need to Evolve (Finance)  [6]
Tuesday 
2:00 pm - 3:30 pm

• Describe how and why VC models have evolved.
• Offer insights on how to successfully navigate the new venture landscape.
• Explain VC valuation methods and investing models.

194 - Financing Beyond the Lead Compound: Attracting Funding for Multiproduct Platforms (Finance)  [7]
Tuesday
10:00 am - 11:30 am

• Show how to build a business plan that conveys value of the company, beyond a lead candidate.
• Describe how to create strategies that attract VC financing and capitalize on the value of product.
• Showcase the potential of the value proposition for the platform and company.

199 - Starting Up Biotechs in the New Normal World (Finance)  [5]
Wednesday 
10:00 am – 11:30 am

• Provide CEO and VC views on how biotech venture fundraising has changed between early 2008 and 2011.
• Review non-VC funding options for start-up biotechs.
• Provide an interactive forum for entrepreneurs to ask questions.

200 - Collaborations and Strategies to Crossing the Valley of Death to Fund Innovative Medicines (Finance)  [8]
Wednesday
2:00 pm - 3:30 pm

• Explore strategies to overcome the challenges and bottlenecks of drug development.
• Highlight current and future projects aimed at transforming drug development.
• Discuss how unique partnerships can bring innovative medicines to patients worldwide.

95 - Innovative Collaborations: Deal Structures for Nonprofit/For-Profit Collaborations (Biotech Patenting and Tech Transfer)  [9]
Thursday, June 30, 2011
8:30 am - 9:45 am

• Describe successful industry collaborations with nonprofits and drafting those clauses in your agreement.
• Explain how collaboration terms vary when one or both of the parties is a non-U.S. entity.
• List structures and terms to avoid in the interest of a successful collaboration.

188 - The Changing BD Environment: Overcoming Our Past to Succeed in the Future (Business Development)  [10]
Tuesday 
2:00 pm - 3:30 pm

• Explain the dynamics (type, economics, timing, roles) driving biotech/pharma collaborations.
• Conceptualize novel approaches to biotech and pharma collaborations.
• Identify key deal showstoppers from either a historical or novel transaction approach.